Malignant lymphoma
Malignant lymphoma (ML) is an immune cell tumor that occurs in lymph nodes and/or extranodal lymphoid tissue. It originates from the malignant transformation of lymphocytes or tissue cells and is a group of solid tumors that are highly curable.
-
Site of disease:
lymph -
Infectious :
Not contagious -
Frequent population:
It is common in middle-aged and elderly people, with work pressure... -
Related symptoms:
Widening of the hilum of the lung itching swollen and tender submandibular lymph nodes splenomegaly weight loss
Related Drugs
Cytarabine Hydrochloride for Injection
Indication: It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.
Manufacturer:
Sinopharm A-Think Pharmaceutical Co., Ltd.
Cytarabine Hydrochloride for Injection
Indication: It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.
Manufacturer:
Han Hui Pharmaceuticals Company Limited
Cytarabine Hydrochloride for Injection
Indication: It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.
Manufacturer:
Harbin Laiboten Pharmaceutical Co., Ltd.
Cytarabine Hydrochloride for Injection
Indication: It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.
Manufacturer:
Harbin Laiboten Pharmaceutical Co., Ltd.
Cytarabine Hydrochloride for Injection
Indication: It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.
Manufacturer:
RenHe Hetero Pharmaceuticals Ltd.
Nimustine hydrochloride
Indication: Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.
Manufacturer:
Hainan General Alliance Pharmaceutical Co., Ltd.
Nimustine hydrochloride
Indication: Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.
Manufacturer:
Yangtze River Pharmaceutical Group Jiangsu HaiCi Biological Pharmaceutical Co., Ltd.
Nimustine hydrochloride
Indication: Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.
Nimustine hydrochloride
Indication: Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.
Manufacturer:
Shandong Ruiying Pioneer Pharmaceutical Co., Ltd.
Nimustine hydrochloride
Indication: Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.